282 related articles for article (PubMed ID: 11895576)
1. Aldosterone as a mediator in cardiovascular injury.
Stier CT; Chander PN; Rocha R
Cardiol Rev; 2002; 10(2):97-107. PubMed ID: 11895576
[TBL] [Abstract][Full Text] [Related]
2. Effect of aldosterone and MR blockade on the brain and the kidney.
Stier CT; Rocha R; Chander PN
Heart Fail Rev; 2005 Jan; 10(1):53-62. PubMed ID: 15947892
[TBL] [Abstract][Full Text] [Related]
3. Aldosterone and aldosterone antagonism in cardiovascular disease: focus on eplerenone (Inspra).
Stier CT; Koenig S; Lee DY; Chawla M; Frishman WH
Heart Dis; 2003; 5(2):102-18. PubMed ID: 12713678
[TBL] [Abstract][Full Text] [Related]
4. Review of aldosterone- and angiotensin II-induced target organ damage and prevention.
Struthers AD; MacDonald TM
Cardiovasc Res; 2004 Mar; 61(4):663-70. PubMed ID: 14985063
[TBL] [Abstract][Full Text] [Related]
5. Aldosterone and specific aldosterone receptor antagonists in hypertension and cardiovascular disease.
Bravo EL
Curr Hypertens Rep; 2003 Apr; 5(2):122-5. PubMed ID: 12642011
[TBL] [Abstract][Full Text] [Related]
6. Evolving role of aldosterone blockers alone and in combination with angiotensin-converting enzyme inhibitors or angiotensin II receptor blockers in hypertension management: a review of mechanistic and clinical data.
Black HR
Am Heart J; 2004 Apr; 147(4):564-72. PubMed ID: 15077068
[TBL] [Abstract][Full Text] [Related]
7. Combination therapy with aldosterone blockade and renin-angiotensin inhibitors confers organ protection.
Sato A; Saruta T; Funder JW
Hypertens Res; 2006 Apr; 29(4):211-6. PubMed ID: 16778327
[TBL] [Abstract][Full Text] [Related]
8. Eplerenone: a selective aldosterone blocker.
Stier CT
Cardiovasc Drug Rev; 2003; 21(3):169-84. PubMed ID: 12931252
[TBL] [Abstract][Full Text] [Related]
9. The promise of selective aldosterone receptor antagonists for the treatment of hypertension and congestive heart failure.
Hameedi A; Chadow HL
Curr Hypertens Rep; 2000 Aug; 2(4):378-83. PubMed ID: 10981173
[TBL] [Abstract][Full Text] [Related]
10. Aldosterone antagonists in hypertension and heart failure.
Mantero F; Lucarelli G
Ann Endocrinol (Paris); 2000 Feb; 61(1):52-60. PubMed ID: 10790593
[TBL] [Abstract][Full Text] [Related]
11. Eplerenone: a selective aldosterone receptor antagonist (SARA).
Delyani JA; Rocha R; Cook CS; Tobert DS; Levin S; Roniker B; Workman DL; Sing YL; Whelihan B
Cardiovasc Drug Rev; 2001; 19(3):185-200. PubMed ID: 11607037
[TBL] [Abstract][Full Text] [Related]
12. Recent studies with eplerenone, a novel selective aldosterone receptor antagonist.
McMahon EG
Curr Opin Pharmacol; 2001 Apr; 1(2):190-6. PubMed ID: 11714095
[TBL] [Abstract][Full Text] [Related]
13. The endothelin-aldosterone axis and cardiovascular diseases.
Rossi GP; Cavallin M; Nussdorfer GG; Pessina AC
J Cardiovasc Pharmacol; 2001 Nov; 38 Suppl 2():S49-52. PubMed ID: 11811378
[TBL] [Abstract][Full Text] [Related]
14. Clinical implications of aldosterone blockade.
Weber MA
Am Heart J; 2002 Nov; 144(5 Suppl):S12-8. PubMed ID: 12422136
[TBL] [Abstract][Full Text] [Related]
15. Aldosterone: cardiovascular assault.
Struthers AD
Am Heart J; 2002 Nov; 144(5 Suppl):S2-7. PubMed ID: 12422134
[TBL] [Abstract][Full Text] [Related]
16. Aldosterone as a mediator of progressive renal disease: pathogenetic and clinical implications.
Epstein M
Am J Kidney Dis; 2001 Apr; 37(4):677-88. PubMed ID: 11273866
[TBL] [Abstract][Full Text] [Related]
17. Eplerenone: cardiovascular protection.
Brown NJ
Circulation; 2003 May; 107(19):2512-8. PubMed ID: 12756192
[TBL] [Abstract][Full Text] [Related]
18. Effects of spironolactone and angiotensin-converting enzyme inhibitor on left ventricular hypertrophy in patients with essential hypertension.
Sato A; Suzuki Y; Saruta T
Hypertens Res; 1999 Mar; 22(1):17-22. PubMed ID: 10221346
[TBL] [Abstract][Full Text] [Related]
19. Pathophysiologic role of the renin-angiotensin-aldosterone and sympathetic nervous systems in heart failure.
Adams KF
Am J Health Syst Pharm; 2004 May; 61 Suppl 2():S4-13. PubMed ID: 15160833
[TBL] [Abstract][Full Text] [Related]
20. Effects of aldosterone and angiotensin II receptor blockade on cardiac angiotensinogen and angiotensin-converting enzyme 2 expression in Dahl salt-sensitive hypertensive rats.
Takeda Y; Zhu A; Yoneda T; Usukura M; Takata H; Yamagishi M
Am J Hypertens; 2007 Oct; 20(10):1119-24. PubMed ID: 17903697
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
